Member login

Forgot Password?
Return to login
Better access. Better health.
The British Generic Manufacturers Association (BGMA) represents the interests of UK-based manufacturers and suppliers of generic and biosimilar medicines and promotes the development and understanding of the generic and biosimilars medicines industry in the United Kingdom.
We have a strong focus on quality
The British Generic Manufacturers Association (BGMA) has launched a forum in conjunction with the MHRA to focus on ensuring the manufacturing quality of generic medicines in the UK.
We reflect our members’ views at UK and European levels
We represent the views and interests of our members and industry generally to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union and the media. Find out more about joining us.

Twitter

15.11.2017
@Sandoz_Global Kavya Gopal appointed chair of the British Biosimilars Assocation (BBA) - for further information see https://t.co/G3SE3X0gxJ
14.11.2017
RT @medicinesforEU: Generic medicines are the cornerstone of European healthcare sustainability. They reduce pressure on healthcare budgets #AccessToMedicines https://t.co/aeOSZZliiq
14.11.2017
RT @BritBiosimilars: BBA Stakeholder Forum Programme - Sharing success & challenges in biosimilars implementation. Last few places for our free event on November 21. Full programme here https://t.co/3j7tar37by Contact ania.swirski@instinctif.com
07.11.2017
RT @BritBiosimilars: On Nov 21, the British Biosimilars Association (BBA) will be staging its second annual conference sign up free here https://t.co/3pdPtYdLrz
03.11.2017
RT @jamesosh: Just published @DHgovuk response to Accelerated Access Review: https://t.co/xFyTixLMt4. Aim is to get breakthrough treatments into the NHS up to 4 years faster - great news for patients & for life sciences.

10 things you need to know

1
Generic medicines meet the same standards of quality, safety and efficacy as originator brands.
2
Generics have to demonstrate that they are bioequivalent to the original product - i.e., they deliver equal medical benefits to the patient.
3
Generic competition saves the NHS more than £13.5bn per annum.
4
The average cost to the NHS of a generic medicine is £3.80, whilst the average cost of a branded medicine is £20.95.
5
On one product alone, based on current usage, the generics industry has saved the taxpayer £1.1bn.
6
In the UK, a free market approach with competition between manufacturers and incentives for GPs to prescribe and pharmacists to dispense generics has led to a high market share (76%) for generic products.
7
Generic prices in the UK are the lowest in the developed world and are constrained by free market competition.
8
The market share that generics reach and the savings they generate are dependent upon national legislation and regulation.
9
Further growth and NHS savings are constrained by regulatory delays and costs, and the actions of some originator companies in trying to avoid or delay generic competition.
10
Competition from generics also stimulates the research based pharmaceutical industry to develop new medicines.